Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
20 January, 2018 12:56 IST
Lupin gets USFDA approval for generic Vibra-Tabs tablet
Source: IRIS | 11 Sep, 2017, 02.52PM
Comments  |  Post Comment

Pharma Major Lupin announced that it has received final approval for its Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s Vibra-Tabs, 100 mg.

Lupin's Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.'s Vibra-Tabs, 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablet USP, 100 mg had US sales of USD 149.9 million (IMS MAT June 2017).

Shares of the company gained Rs 8.85, or 0.91%, to trade at Rs 977.00. The total volume of shares traded was 272,593 at the BSE (2.43 p.m., Monday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Reliance Q3 profit up 25.5%; GRM at USD 11.6/bbl - 19-Jan-2018 18:34
HDFC Bank Q3 net grows 20% to Rs 41.51 bn - 19-Jan-2018 18:07
Wipro Q3 earnings fall 12% q-o-q to Rs 19.3 bn - 19-Jan-2018 17:56
Lupin launches generic Vibra-Tabs tablet in US - 19-Jan-2018 15:56
HCL Tech Q3 profit jumps 6% to Rs 21.94 bn - 19-Jan-2018 11:45
Suven Life Sciences secures 2 overseas product patents - 18-Jan-2018 15:26
Yes Bank Q3 profit rises 22% to Rs 10.76 bn - 18-Jan-2018 15:24
Sanghvi Forging & Engg bags new orders worth Rs 110 mn - 18-Jan-2018 10:17
Tata Consultancy Services expands partnership with Shure Inc - 18-Jan-2018 10:13
Ashok Leyland signs Lol with Phinergy, Israel for high energy EV - 17-Jan-2018 16:20
Transformers & Rectifiers India receives Rs 1.26 bn order - 17-Jan-2018 16:05
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer